...
首页> 外文期刊>Therapeutic Drug Monitoring >Optimal storage temperature and matrix before analyzing mycophenolic acid
【24h】

Optimal storage temperature and matrix before analyzing mycophenolic acid

机译:分析霉酚酸之前的最佳储存温度和基质

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The immunosuppressant mycophenolic acid (MPA) is widely used in solid organ transplantation and increasingly in hematological conditions and autoimmune disease. Concentration monitoring is generally restricted to specialist laboratories associated with transplant centers to which samples are referred, and delays in transit may occur both from the patient to the local laboratory and from there to the specialist laboratory. The instability of the mycophenolate glucuronides in plasma is well described, but the data on MPA stability in patient samples are limited, particularly in whole blood. This study was designed to assess the stability of MPA in patient samples and to establish the correct sample type and optimal transport conditions for therapeutic drug monitoring. Methods: Whole-blood samples received in the laboratory for MPA estimation within 2 hours of phlebotomy were aliquoted, separated, and stored at a range of temperatures designed to mimic the range of transit times and conditions seen in this laboratory. Ten whole-blood samples were stored for a maximum of 4 weeks at 4°C, 21°C, or 35°C and plasma at-20°C, 4°C, 21°C, and 35°C. MPA concentrations were measured by liquid chromatography-tandem mass spectrometry. Results: In whole blood at 35°C, there was a significant increase (P = 0.004) in median MPA concentration over time, but concentrations decreased in some samples. At 21°C and 4°C, there were more modest increases (P = 0.04 and 0.02). In plasma at 35°C, there was a significant increase from day 3 to day 28, then a decrease to day 96 in measured MPA concentration. At 21°C, there was a progressive increase in concentration from 7 to 96 days of storage (P < 0.0001). At 4°C and-20°C, plasma samples were stable for 28 days after collection, but at-20°C, there was a subsequent median increase in concentration of 15.2% at day 96. Conclusions: Samples should be separated as soon as practicable after collection and stored at-20°C or 4°C before transport to the analytical laboratory using subambient temperatures if possible.
机译:背景:免疫抑制剂麦考酚酸(MPA)广泛用于实体器官移植,并越来越多地用于血液学疾病和自身免疫性疾病。浓度监测通常仅限于与样品所涉及的移植中心相关的专业实验室,并且从患者到本地实验室以及从那里到专业实验室的运输都可能出现延迟。血浆中麦考酚酸酯葡糖醛酸苷的不稳定性已得到很好的描述,但是患者样品中MPA稳定性的数据有限,特别是在全血中。本研究旨在评估患者样品中MPA的稳定性,并建立用于治疗药物监测的正确样品类型和最佳运输条件。方法:将等分采血后2小时内在实验室中接受的用于MPA评估的全血样品等分,分离并保存在一定的温度范围内,该温度旨在模拟该实验室观察到的转运时间和条件范围。十个全血样品分别在4°C,21°C或35°C下保存最多4周,在20°C,4°C,21°C和35°C下保存血浆。通过液相色谱-串联质谱法测量MPA浓度。结果:在35°C的全血中,MPA的中值浓度随时间显着增加(P = 0.004),但某些样品中的浓度下降。在21°C和4°C时,温和的增加幅度更大(P = 0.04和0.02)。在35°C的血浆中,从第3天到第28天有显着增加,然后在测量的MPA浓度中下降到第96天。在21°C下,从存储7天到96天浓度逐渐增加(P <0.0001)。在4°C和-20°C下,血浆样品收集后稳定了28天,但在20°C下,第96天浓度随后出现了15.2%的中值升高。结论:应尽快分离样品收集后应尽可能地可行,并在可能的情况下,在低于室温的温度下运输到分析实验室之前,应先储存在20°C或4°C下。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号